HF Advisory Group LLC Raises Stock Holdings in Novartis AG (NYSE:NVS)

HF Advisory Group LLC boosted its stake in Novartis AG (NYSE:NVS) by 7.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,045 shares of the company’s stock after purchasing an additional 636 shares during the quarter. HF Advisory Group LLC’s holdings in Novartis were worth $880,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of NVS. Aaron Wealth Advisors LLC raised its position in shares of Novartis by 7.5% during the 4th quarter. Aaron Wealth Advisors LLC now owns 14,117 shares of the company’s stock valued at $1,374,000 after buying an additional 986 shares in the last quarter. IAM Advisory LLC increased its stake in Novartis by 1.7% in the fourth quarter. IAM Advisory LLC now owns 15,160 shares of the company’s stock valued at $1,475,000 after acquiring an additional 247 shares during the last quarter. HB Wealth Management LLC raised its position in Novartis by 8.6% during the fourth quarter. HB Wealth Management LLC now owns 6,744 shares of the company’s stock valued at $656,000 after purchasing an additional 534 shares in the last quarter. Financial & Tax Architects LLC lifted its stake in Novartis by 14.1% during the fourth quarter. Financial & Tax Architects LLC now owns 5,522 shares of the company’s stock worth $537,000 after purchasing an additional 683 shares during the last quarter. Finally, Arkadios Wealth Advisors boosted its holdings in shares of Novartis by 38.0% in the 4th quarter. Arkadios Wealth Advisors now owns 8,487 shares of the company’s stock worth $826,000 after purchasing an additional 2,336 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Novartis Stock Performance

Shares of NVS stock opened at $97.51 on Friday. The company has a market capitalization of $199.30 billion, a P/E ratio of 11.32, a PEG ratio of 1.36 and a beta of 0.57. Novartis AG has a fifty-two week low of $92.35 and a fifty-two week high of $120.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The stock has a 50 day moving average price of $100.61 and a two-hundred day moving average price of $108.99.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The company had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same period in the prior year, the business posted $1.74 earnings per share. Analysts expect that Novartis AG will post 7.63 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NVS shares. Erste Group Bank reissued a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. HSBC downgraded shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets upped their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. According to MarketBeat.com, Novartis currently has a consensus rating of “Hold” and an average target price of $121.50.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.